sb 203580 has been researched along with quinuclidines in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (quinuclidines) | Trials (quinuclidines) | Recent Studies (post-2010) (quinuclidines) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 2,567 | 453 | 991 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; Chen, K; Wang, YL; Zhan, J; Zhang, ZZ | 1 |
1 other study(ies) available for sb 203580 and quinuclidines
| Article | Year |
|---|---|
Penehyclidine hydrochloride attenuates LPS-induced iNOS production by inhibiting p38 MAPK activation in endothelial cells.
Topics: Analysis of Variance; Blotting, Western; Endothelial Cells; Enzyme Activation; Humans; Imidazoles; Lipopolysaccharides; Nitric Oxide Synthase Type II; p38 Mitogen-Activated Protein Kinases; Pyridines; Quinuclidines | 2012 |